Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype

Abstract The use of sentinel node biopsy (SNB) following neoadjuvant chemotherapy (NAC) for patients with cN1 breast cancer is controversial. Improvements of negative predictive value (NPV) by axillary ultrasound (AUS), which corresponds to the accurate prediction rate of node-negative status after...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yurina Maeshima, Takehiko Sakai, Akiko Ogiya, Yoko Takahashi, Yumi Miyagi, Yumi Kokubu, Tomo Osako, Yoshinori Ito, Shunji Takahashi, Shinji Ohno, Takayuki Ueno
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/60aecae89c8648169746a7fbc098b127
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:60aecae89c8648169746a7fbc098b127
record_format	dspace
spelling	oai:doaj.org-article:60aecae89c8648169746a7fbc098b1272021-12-02T15:00:13ZAssessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype10.1038/s41598-021-89738-82045-2322https://doaj.org/article/60aecae89c8648169746a7fbc098b1272021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89738-8https://doaj.org/toc/2045-2322Abstract The use of sentinel node biopsy (SNB) following neoadjuvant chemotherapy (NAC) for patients with cN1 breast cancer is controversial. Improvements of negative predictive value (NPV) by axillary ultrasound (AUS), which corresponds to the accurate prediction rate of node-negative status after NAC, would lead to decreased FNR of SNB following NAC. In this study, we retrospectively investigated the accurate prediction rate of NPV by AUS after NAC in patients with cytologically node-positive breast cancer treated between January 2012 and December 2016. Of 279 eligible patients, the NPV was 49.2% in all patients, but varied significantly by tumor subtype (p < 0.001) and tumor response determined by magnetic resonance imaging (MRI) (p = 0.0003). Of the 23 patients with clinically node negative (ycN0) by AUS and clinical complete response in primary lesion by MRI, the NPV was 100% in patients with HR±/HER2+ or HR−/HER2− breast cancer. In conclusion, regarding FNR reduction post-NAC, it will be of clinical value to take tumor subtype and primary tumor response using MRI into account to identify patients for SNB after NAC.Yurina MaeshimaTakehiko SakaiAkiko OgiyaYoko TakahashiYumi MiyagiYumi KokubuTomo OsakoYoshinori ItoShunji TakahashiShinji OhnoTakayuki UenoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yurina Maeshima Takehiko Sakai Akiko Ogiya Yoko Takahashi Yumi Miyagi Yumi Kokubu Tomo Osako Yoshinori Ito Shunji Takahashi Shinji Ohno Takayuki Ueno Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
description	Abstract The use of sentinel node biopsy (SNB) following neoadjuvant chemotherapy (NAC) for patients with cN1 breast cancer is controversial. Improvements of negative predictive value (NPV) by axillary ultrasound (AUS), which corresponds to the accurate prediction rate of node-negative status after NAC, would lead to decreased FNR of SNB following NAC. In this study, we retrospectively investigated the accurate prediction rate of NPV by AUS after NAC in patients with cytologically node-positive breast cancer treated between January 2012 and December 2016. Of 279 eligible patients, the NPV was 49.2% in all patients, but varied significantly by tumor subtype (p < 0.001) and tumor response determined by magnetic resonance imaging (MRI) (p = 0.0003). Of the 23 patients with clinically node negative (ycN0) by AUS and clinical complete response in primary lesion by MRI, the NPV was 100% in patients with HR±/HER2+ or HR−/HER2− breast cancer. In conclusion, regarding FNR reduction post-NAC, it will be of clinical value to take tumor subtype and primary tumor response using MRI into account to identify patients for SNB after NAC.
format	article
author	Yurina Maeshima Takehiko Sakai Akiko Ogiya Yoko Takahashi Yumi Miyagi Yumi Kokubu Tomo Osako Yoshinori Ito Shunji Takahashi Shinji Ohno Takayuki Ueno
author_facet	Yurina Maeshima Takehiko Sakai Akiko Ogiya Yoko Takahashi Yumi Miyagi Yumi Kokubu Tomo Osako Yoshinori Ito Shunji Takahashi Shinji Ohno Takayuki Ueno
author_sort	Yurina Maeshima
title	Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
title_short	Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
title_full	Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
title_fullStr	Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
title_full_unstemmed	Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
title_sort	assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/60aecae89c8648169746a7fbc098b127
work_keys_str_mv	AT yurinamaeshima assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype AT takehikosakai assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype AT akikoogiya assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype AT yokotakahashi assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype AT yumimiyagi assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype AT yumikokubu assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype AT tomoosako assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype AT yoshinoriito assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype AT shunjitakahashi assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype AT shinjiohno assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype AT takayukiueno assessmentofaxillarynodestatusbyultrasoundafterneoadjuvantchemotherapyinpatientswithclinicallynodepositivebreastcanceraccordingtobreastcancersubtype
_version_	1718389203622952960

Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype

Ejemplares similares